Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Amgen has submitted a supplemental new drug application (sNDA) seeking expanded approval for Otezla in adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.